CN107184756A - One kind repairs neurovascular pharmaceutical composition and preparation method thereof - Google Patents
One kind repairs neurovascular pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN107184756A CN107184756A CN201710039512.2A CN201710039512A CN107184756A CN 107184756 A CN107184756 A CN 107184756A CN 201710039512 A CN201710039512 A CN 201710039512A CN 107184756 A CN107184756 A CN 107184756A
- Authority
- CN
- China
- Prior art keywords
- parts
- neurovascular
- pharmaceutical composition
- ophidia
- prepare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000008439 repair process Effects 0.000 title claims description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 34
- 241000270295 Serpentes Species 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 241000489492 Arisaema Species 0.000 claims abstract description 26
- 210000000941 bile Anatomy 0.000 claims abstract description 26
- 210000003205 muscle Anatomy 0.000 claims abstract description 25
- 241000345998 Calamus manan Species 0.000 claims abstract description 22
- 241000405414 Rehmannia Species 0.000 claims abstract description 22
- 241001145009 Sophora alopecuroides Species 0.000 claims abstract description 22
- 235000018905 epimedium Nutrition 0.000 claims abstract description 22
- 235000012950 rattan cane Nutrition 0.000 claims abstract description 22
- 241000005787 Cistanche Species 0.000 claims abstract description 21
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 21
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 21
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 21
- 241001016310 Epimedium grandiflorum Species 0.000 claims abstract description 20
- 241001411234 Sagina subulata Species 0.000 claims abstract description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 20
- 239000000828 canola oil Substances 0.000 claims abstract description 20
- 235000019519 canola oil Nutrition 0.000 claims abstract description 20
- 239000011780 sodium chloride Substances 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000605 extraction Methods 0.000 claims abstract description 15
- 235000010204 pine bark Nutrition 0.000 claims abstract description 15
- 241000801118 Lepidium Species 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 21
- 241000219095 Vitis Species 0.000 claims description 20
- 239000002026 chloroform extract Substances 0.000 claims description 19
- 239000012153 distilled water Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 239000011812 mixed powder Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 230000033228 biological regulation Effects 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 8
- 210000002569 neuron Anatomy 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 7
- 230000004224 protection Effects 0.000 abstract description 6
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 230000033115 angiogenesis Effects 0.000 abstract description 3
- 230000001964 calcium overload Effects 0.000 abstract description 3
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000012010 growth Effects 0.000 abstract description 2
- 230000036542 oxidative stress Effects 0.000 abstract description 2
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 240000006365 Vitis vinifera Species 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 10
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 5
- 241000018646 Pinus brutia Species 0.000 description 5
- 235000011613 Pinus brutia Nutrition 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NYGZYUAVZPIKBZ-BDJLRTHQSA-N Kushenin Natural products O(C)c1c(O)cc2O[C@H]3[C@@H](c2c1)COc1c3ccc(O)c1 NYGZYUAVZPIKBZ-BDJLRTHQSA-N 0.000 description 2
- NYGZYUAVZPIKBZ-UHFFFAOYSA-N Lespedezol D1 Natural products C1OC2=CC(O)=CC=C2C2C1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical compound C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 2
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- NYGZYUAVZPIKBZ-ZBEGNZNMSA-N lespedezol D1 Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-ZBEGNZNMSA-N 0.000 description 2
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- ZSBXGIUJOOQZMP-BHPKHCPMSA-N sophoridine Chemical compound C1CC[C@@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-BHPKHCPMSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 241000424773 Epimedium alpinum Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 1
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930185474 acteoside Natural products 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- -1 amine alkaloid Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000272 myelencephalon Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008280 toxic mechanism Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Neurovascular pharmaceutical composition and preparation method thereof is repaired the invention discloses one kind, described pharmaceutical composition is made up of the raw material below according to mass parts：20 30 parts of glutinous rehmannia, 5 15 parts of pine bark, 2 10 parts of grape pip, 13 parts of Canola Oil, 16 24 parts of wide muscle rattan, 16 20 parts of Sagina subulata, 10 14 parts of arisaema cum bile, 4 10 parts of lepidium seed, 15 parts of ophidia, 10 20 parts of Sophora alopecuroide, 4 10 parts of saline cistanche, 4 10 parts of barrenwort；Each raw material is size-reduced, water is extracted, ethanol is extracted, means are concentrated is prepared into thick paste for chloroform extraction etc.；Medicine energy Mutiple Targets of the present invention act on neurovascular Protection path and damage path；Neurotoxicity can be resisted, neuronal cell is protected；Neurotrosis inflammation can be suppressed；It is avoided that neuron oxidativestress damage caused by activating oxide accumulation；Cell paraplasm can be mitigated, suppress Apoptosis；Angiogenesis and nerve growth reparation can be promoted；Intracellular calcium overload can be suppressed, be that neurovascular repairing and treating proposes new theory and thinking.
Description
Technical field
It is specifically a kind of neurovascular pharmaceutical composition of reparation and its preparation side the present invention relates to pharmaceutical technology field
Method.
Background technology
Cranial vascular disease is one of big fatal disease of the mankind three, and the incidence of disease is high, seriously endangers human health, to society and
Family brings huge burden；Neural blood vessel unit is made up of neuron, spongiocyte and capilary, is deposited between each cell component
In complicated interaction, the entirety of the coordinating and unifying is constituted；After cerebral ischemia, obstacle occurs for the signal transmission in NVU between each composition,
So as to cause neuron and extracellular matrix destruction, the generation of cerebral infarction is ultimately resulted in；Hemorrhagic Transformation is ischemic after cerebral infarction
Substrate degradation in core space capilary basilar memebrane causes blood constituent to leak into what is formed in tissue, capilary matrix it is impaired with
A variety of stromatin enzyme families are relevant with specific proteases activation system up-regulated expression, and cerebral hemorrhage wind can be increased using medicine for treating thrombus
Danger, wherein with the bleeding risk highest of plasminogen activator, after cerebral ischemia, can each cell component, which survive, depends on each cell
W-response, the treatment of palsy should prevent cell death, while to protect NVU allomeric function；Research shows, cerebral ischemia
Afterwards, trophic factors can promote neural blood vessel plasticity and recovery, various growth factors, such as nerve growth factor, into fiber finer
The intracellular growth factor, glial cell line-derived neurotrophic factor and BDNF, make with certain neuroprotection
With, but these growth factor molecule amounts are relatively bigger than normal, it is difficult to reach brain parenchym through blood-brain barrier.
In past research process, for the dark space of ischemic half and cerebral ischemia cascade reaction mechanism, such as acid poisoning, emerging
Put forth energy acidic amino acid increase, the release of intracellular calcium overload, free radical, lipid peroxidation, the link research and development such as inflammatory process and apoptosis
Medicine, 140 multinomial clinical research altogether, test 250 multi-medicaments it is alone or be used in combination because can not finally improve apoplexy suffer from
Person's clinical symptoms and life quality, in addition it is harmful, and cause experiment to terminate；The proposition of NVU concepts is research neuron, capilary
And inner link between Deiter's cells and collective provide the dissection of holistic approach to the response under brain pathological state
Basis is learned, in a variety of nervous system disease processes such as apoplexy, vascular dementia, migraines, multiple sclerosis, or even aging
In, NVU various kinds of cell compositions should be protected by and be repaired simultaneously；How to study and show after cerebral ischemia or other brain myopathies
NVU W-response and strain mechanism, is current research direction；NVU sensitive composition has vulnerability, if can not be timely
Recover perfusion, the recovery of overall structure function will receive limitation；Still lack that price is low, eutherapeutic nerve on the market at present
Medicine is protected, accordingly, it would be desirable to which based on NVU overall networks, brain cell can be protected and recover brain function by working out one kind, and curative effect is aobvious
Write, be easy to the medicine absorbed, toxic side effect is small.
The content of the invention
Neurovascular pharmaceutical composition and preparation method thereof is repaired it is an object of the invention to provide one kind, with solution
State the problem of being proposed in background technology.
To achieve the above object, the present invention provides following technical scheme：
One kind repairs neurovascular pharmaceutical composition, is made up of the raw material below according to mass parts：20-30 parts of glutinous rehmannia,
5-15 parts of pine bark, 2-10 parts of grape pip, 1-3 parts of Canola Oil, wide 16-24 parts of muscle rattan, 16-20 parts of Sagina subulata, courage south
10-14 parts of star, 4-10 parts of lepidium seed, 1-5 parts of ophidia, 10-20 parts of Sophora alopecuroide, 4-10 parts of saline cistanche, 4-10 parts of barrenwort.
It is used as further scheme of the invention：It is described to repair neurovascular pharmaceutical composition, by below according to quality
The raw material of part is made：22-28 parts of glutinous rehmannia, 8-12 parts of pine bark, 4-8 parts of grape pip, 1-3 parts of Canola Oil, wide muscle rattan 18-
22 parts, 17-19 parts of Sagina subulata, 11-13 parts of arisaema cum bile, 6-8 parts of lepidium seed, 2-4 parts of ophidia, 14-16 parts of Sophora alopecuroide, saline cistanche
6-8 parts, 6-8 parts of barrenwort.
It is used as further scheme of the invention：It is described to repair neurovascular pharmaceutical composition, by below according to quality
The raw material of part is made：25 parts of glutinous rehmannia, 10 parts of pine bark, 6 parts of grape pip, 2 parts of Canola Oil, 20 parts of wide muscle rattan, Sagina subulata
18 parts, 12 parts of arisaema cum bile, 7 parts of lepidium seed, 3 parts of ophidia, 15 parts of Sophora alopecuroide, 7 parts of saline cistanche, 7 parts of barrenwort.
It is used as further scheme of the invention：The preparation method for repairing neurovascular pharmaceutical composition, including
Following steps：
1) glutinous rehmannia, pine bark, wide muscle rattan, Sagina subulata, arisaema cum bile, arisaema cum bile, saline cistanche and barrenwort are weighed by formula, washed
Only mechanical crushing is used after drying, is placed in marmite, the distilled water of 10-15 times of weight of solid content is added, intense fire is fried open, turns text
Fire decocts 30-50min, filters to obtain primary filtrate, and filter residue adds the distilled water of 10 times of amounts again, and slow fire is simmered 60-100min, filtered
Secondary filtrate, filtrate mixing twice, separation supernatant is standby；
2) ophidia of formula ratio is cleaned, 60-80 mesh is crushed to after slow fire frying 5-10min, and to obtain ophidia powder standby；
3) grape pip of formula ratio, Sophora alopecuroide are pulverized and sieved, obtains 60-80 mesh mixed powders standby；
4) by step 2) in prepare ophidia powder and step 3) in prepare mixed powder insert in extractor, add quality
Fraction is 95% ethanol solution, and stirring extraction obtains just extracted extract；
5) by step 4) in first extracted extract with 3 times amount purified water ultrasonic dissolutions, add sodium hydroxide solution regulation pH
To 1-3.5, add and stir extraction with the isometric chloroform of purified water, a layer chloroform extract is removed after layering, concentrate drying is obtained
Chloroform extract medicinal extract, chloroform is reclaimed；
6) by the Canola Oil of formula ratio and step 1) prepare supernatant and step 5) in prepare chloroform portion
Position medicinal extract mixing, and in cooling down condensing removing moisture under vacuum condition, obtain thick paste；
7) by step 6) in prepare thick paste 2-3d is refrigerated in 0-4 DEG C of freezer, obtain pharmaceutical composition.
It is used as further scheme of the invention：It is described to repair the neurovascular frequent regulation prescription legal system of pharmaceutical composition
For into for treating and repairing neurovascular pulvis, granule, pill, capsule, tablet.
The pharmacological action of each medicine is as follows in the present invention：
1. glutinous rehmannia：It is sweet, slightly warm in nature；Return liver and kidney channel；For blood deficiency chlorosis, palpitation and severe palpitation, irregular menstruation, metrostaxis,
The deficiency of liver-yin and kidney-yin, soreness and weakness of waist and knees, osteopyrexia and fever, night sweat seminal emission, Heat Diabetes, dizziness, tinnitus, chin hair is early white；The methanol of glutinous rehmannia 70%
Extract suppresses rat platelet aggregation caused by ADP, and has antithrombase effect, rat diffusivity blood caused by induced by endotoxin
Intravascular coagulation has antagonism；Catalpol is one of active ingredient of glutinous rehmannia, and with a variety of pharmacological activity, Catalpol is by adjusting cell
The expression of apoptosis-related genes, activation neuron, improve antioxidant ability of organism, it can promote axon regeneration, mitigate brain blood
In endothelial tube water, promote ischemic brain area Angiogenesis and neurological functional recovery, there is protrusion to classical brain damage model
Therapeutic effect, shows to NVU Global Macroses and repairing, there is active treatment to act on；
2. pine bark：It is bitter, puckery, it is warm-natured；Return lung；Large intestine channel；For dispelling wind and eliminating dampness；Promoting blood circulation and hemostasis, expelling pus and promoting granulation；Cure mainly
Treating rheumatic ostealgia；Traumatic injury；Incised wound；Discharging fresh blood stool；Protracted dysentery；Eczema；Burn and scald, ulcer does not close up long；Lipoprotein can be suppressed
Oxidation and DNA damage caused by hydroxy radical；Antioedematous；Anti-inflammatory and immunological regulation；Blood of human body inner cholesterol content is reduced,
Improve the oxidation resistance of blood plasma and adjust plasma lipoprotein ratio；Extend the ascorbic life-span, activation vitamin C and Wei Sheng
Plain E, being used cooperatively with carotenoidses such as astaxanthin etc. has gain effect；
3. grape pip：Contain polyphenols in grape pip, mainly there is catechin and OPC class；Contain thick egg
In vain, amino acid and vitamin A, E, D, K, P and various trace elements, such as calcium, zinc, iron, magnesium, copper, potassium, sodium, manganese, cobalt；Have
Potent radicals scavenging effect, activity in vivo is high, and is easy to absorb, and can improve blood circulation, reduce the low-density in blood
Cholesterol, prevents cholesterol hoarding on ductus arteriosus wall, reduces platelet aggregation, safeguards the smooth circulation of blood, it is to avoid artery
Hardening, it has strong anti-oxidation ability, stable collagen, maintains elastin, protect blood vessel elasticity, collagen and elastin
Connection, blood vessel and muscle between tissue have substantial connection, so as to reach the purpose of reduction oedema incidence；OPC it is small
Molecular structure can penetrating blood-brain barrier there is provided and strengthen intracerebral oxidation resistance, the lesion of prevention brain cell and blood vessel and old
Change, and then reduce the risk of senile dementia, apoplexy and cerebral infarction；Proflavanol contain abundant bioflavonoid, be strength essence
Magnificent molecule, for Green Tea Extract free radical and the health for safeguarding microfilament blood vessel.
4. Canola Oil：Tool is significantly reduced T-CHOL and LDL-C effect in blood plasma；
The formation of thromboxane in external blood platelet can be reduced, coagulating platelets is reduced, there is extension effect to blood coagulating time, so that
Alleviate thrombosis.
5. wide muscle rattan：Cool in nature, mildly bitter flavor, enter liver, spleen two are passed through；Containing quaternary amine alkaloid, predominantly former small-sized palm leaf is prevented
Own alkali and a small amount of jateorrhizine, are secondly the magnoflorine of aporphine type and choline, wide muscle rattan alkali, wide muscle rattan lactone, the heart of amine
The compositions such as leaf width muscle alcohol, cupreol, glucan, have effects that to stimulate the circulation of the blood and cause the muscles and joints to relax, wind-expelling pain-stopping, for treat arthralgia pain due to rheumatism,
The diseases such as sciatica, lumbar muscle strain, traumatic injury.
6. Sagina subulata：It is cool in nature；Sweet-bitter flavor；Return liver, lung channel；Calming liver and clearing heat, promoting diuresis to remove toxic substance；Control enteritis, dysentery, infectiousness liver
Inflammation, nephritic dropsy, urinary tract infections, infantile malnutrition, pinkeye mesh screen, aphtha head sore, nameless sores or boils.
7. arisaema cum bile：Bitter cold, micro-pungent, it is cool.Return lung, liver, the spleen channel；Clearing heat and eliminating phlegm, dispelling wind and relieving convulsion.For phlegm-heat cough, cough up
Phlegm Huang is thick, middle wind phlegm fan, demented frightened epilepsy.
8. lepidium seed：
9. ophidia：It is sweet, it is mild-natured；Return liver warp；There is wind-dispelling, effect of dredging collateral, only convulsion is numb for treating rheumatoid arthritis stubborn
Wooden contraction, middle air port eye fish sticking its mouth out of the water oblique, hemiplegia, tic spasm, lockjaw, leprosy, mange.
10. Sophora alopecuroide：It is bitter, cold in nature；Return stomach, large intestine channel；Heat-clearing and damp-drying drug, analgesic, desinsection；The chemical composition master of Sophora alopecuroide
If protein, carbohydrate, organic acid, flavonoids, pigment and alkaloid；In sophora alopecuroides extract containing Banlangen, Sophoridine,
Chinese scholartree peace alkali, sophocarpine, kushenin etc., with clearing heat and detoxicating, the effect such as anti-inflammation, active ingredient can be used for neuro-protective or
Repair cerebral ischemia re-pouring injured, kushenin is homogenized prepared experimental rat LADA myelencephalon to Whole Guinea Pig spinal cord
Scorching model can play protection myelin result integrality and neuroprotection, can suppress neurotrosis inflammation.
11. saline cistanche：It is sweet, salty；It is warm-natured；Return kidney, large intestine channel；Kidney-replenishing；Benefiting essence-blood；Ease constipation road；Main decline of kidney-YANG；Essence
The impotence of blood deficiency；Seminal emission；Gonorrhoea；The frequent micturition heeltap；Pain in the back flaccidity of lower limbs；Tinnitus mesh is spent；Menstruation is spread out the phase；Fertility；Dry constipation of intestines；
Acteoside in cistanche extracts has protective effect to the PC12 cell models for lacking sugared anoxia-induced apoptosis, can improve second
Phatidylcholine transferase active, increases intracellular levels of acetylcholine.
12. barrenwort：It is pungent, sweet；It is warm-natured；Barrenwort contains icariine, volatile oil, ceryl alcohol, phytosterol, tannin, dimension
The compositions such as raw element E；There are decompression, hypoglycemic, diuresis, kobadrin and the effect of vitamin E sample；Cardiovascular and cerebrovascular blood flow can be increased
Amount, promotes hematopoiesis function, immunologic function and Bone m etabolism, with anti-aging, it is antitumor the effects such as；Excessive sheep in Shorthorned Epimedium P.E
The hydrolysis of leaves of pulse plants glycosides energy acetylcholine esterase inhibition, increases intracerebral levels of acetylcholine.
Compared with prior art, the beneficial effects of the invention are as follows：Medicine of the present invention is based on cerebral ischemia can central and surrounding
Property the calcium ion toxic mechanism that relies on of brain protection mechanism, glutamate receptor protection and damage mechanisms, non-glutamic acid, breach nerve
The conventional frame of Protective strategy, can Mutiple Targets act on neurovascular Protection path and damage path；Nervous toxicity can be resisted
Property, protect neuronal cell；Neurotrosis inflammation can be suppressed；It is avoided that neuron oxidative stress caused by activating oxide accumulation
Damage；Cell paraplasm can be mitigated, suppress Apoptosis；Angiogenesis and nerve growth reparation can be promoted；Cell can be suppressed
Interior Calcium overload；Manner of formulation of the present invention is simple, and production cost is low, and good absorbing effect, duration of efficacy is long, and curative effect shows
Write, have no side effect, it is safe；Made from pure Chinese medicine formula, selected medicinal material compatibility is suitable, meet traditional Chinese medicine and pharmacy and modern doctor
Pharmaceutical theory, is conducive to sufferer to mitigate symptom in time, can reach the purpose treated both principal and secondary aspect of disease, and the property of medicine and drug effect have diversity,
The characteristics of its active ingredient has multipath, Mutiple Targets, too many levels, manifold effect, can send out for different neure damage mechanism
The effect of waving, and by the reasonable compatibility of the present invention, realize Synergistic and attenuation synergistic purpose, be neurovascular repairing and treating
New theory and thinking is proposed, should be widely promoted and apply.
Embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
One kind repairs neurovascular pharmaceutical composition, is made up of the raw material below according to mass parts：20 parts of glutinous rehmannia, pine tree
5 parts of skin, 2 parts of grape pip, 1 part of Canola Oil, 16 parts of wide muscle rattan, 16 parts of Sagina subulata, 10 parts of arisaema cum bile, 4 parts of lepidium seed, crow
1 part of sheath snake, 10 parts of Sophora alopecuroide, 4 parts of saline cistanche, 4 parts of barrenwort.
The preparation method for repairing neurovascular pharmaceutical composition, comprises the following steps：
1) glutinous rehmannia, pine bark, wide muscle rattan, Sagina subulata, arisaema cum bile, arisaema cum bile, saline cistanche and barrenwort are weighed by formula, washed
Only mechanical crushing is used after drying, is placed in marmite, the distilled water of 10-15 times of weight of solid content is added, intense fire is fried open, turns text
Fire decocts 30-50min, filters to obtain primary filtrate, and filter residue adds the distilled water of 10 times of amounts again, and slow fire is simmered 60-100min, filtered
Secondary filtrate, filtrate mixing twice, separation supernatant is standby；
2) ophidia of formula ratio is cleaned, 60-80 mesh is crushed to after slow fire frying 5-10min, and to obtain ophidia powder standby；
3) grape pip of formula ratio, Sophora alopecuroide are pulverized and sieved, obtains 60-80 mesh mixed powders standby；
4) by step 2) in prepare ophidia powder and step 3) in prepare mixed powder insert in extractor, add quality
Fraction is 95% ethanol solution, and stirring extraction obtains just extracted extract；
5) by step 4) in first extracted extract with 3 times amount purified water ultrasonic dissolutions, add sodium hydroxide solution regulation pH
To 1-3.5, add and stir extraction with the isometric chloroform of purified water, a layer chloroform extract is removed after layering, concentrate drying is obtained
Chloroform extract medicinal extract, chloroform is reclaimed；
6) by the Canola Oil of formula ratio and step 1) prepare supernatant, step 5) in prepare chloroform extract leaching
Cream is mixed, and in cooling down condensing removing moisture under vacuum condition, obtains thick paste；
7) by step 6) in prepare thick paste 2-3d is refrigerated in 0-4 DEG C of freezer, obtain pharmaceutical composition.
Embodiment 2
One kind repairs neurovascular pharmaceutical composition, is made up of the raw material below according to mass parts：30 parts of glutinous rehmannia, pine tree
15 parts of skin, 10 parts of grape pip, 3 parts of Canola Oil, 24 parts of wide muscle rattan, 20 parts of Sagina subulata, 14 parts of arisaema cum bile, lepidium seed 10
Part, 5 parts of ophidia, 20 parts of Sophora alopecuroide, 10 parts of saline cistanche, 10 parts of barrenwort.
The preparation method for repairing neurovascular pharmaceutical composition, comprises the following steps：
1) glutinous rehmannia, pine bark, wide muscle rattan, Sagina subulata, arisaema cum bile, arisaema cum bile, saline cistanche and barrenwort are weighed by formula, washed
Only mechanical crushing is used after drying, is placed in marmite, the distilled water of 10-15 times of weight of solid content is added, intense fire is fried open, turns text
Fire decocts 30-50min, filters to obtain primary filtrate, and filter residue adds the distilled water of 10 times of amounts again, and slow fire is simmered 60-100min, filtered
Secondary filtrate, filtrate mixing twice, separation supernatant is standby；
2) ophidia of formula ratio is cleaned, 60-80 mesh is crushed to after slow fire frying 5-10min, and to obtain ophidia powder standby；
3) grape pip of formula ratio, Sophora alopecuroide are pulverized and sieved, obtains 60-80 mesh mixed powders standby；
4) by step 2) in prepare ophidia powder and step 3) in prepare mixed powder insert in extractor, add quality
Fraction is 95% ethanol solution, and stirring extraction obtains just extracted extract；
5) by step 4) in first extracted extract with 3 times amount purified water ultrasonic dissolutions, add sodium hydroxide solution regulation pH
To 1-3.5, add and stir extraction with the isometric chloroform of purified water, a layer chloroform extract is removed after layering, concentrate drying is obtained
Chloroform extract medicinal extract, chloroform is reclaimed；
6) by the Canola Oil of formula ratio and step 1) prepare supernatant, step 5) in prepare chloroform extract leaching
Cream is mixed, and in cooling down condensing removing moisture under vacuum condition, obtains thick paste；
7) by step 6) in prepare thick paste 2-3d is refrigerated in 0-4 DEG C of freezer, obtain pharmaceutical composition.
Embodiment 3
One kind repairs neurovascular pharmaceutical composition, is made up of the raw material below according to mass parts：22 parts of glutinous rehmannia, pine tree
8 parts of skin, 4 parts of grape pip, 1 part of Canola Oil, 18 parts of wide muscle rattan, 17 parts of Sagina subulata, 11 parts of arisaema cum bile, 6 parts of lepidium seed, crow
2 parts of sheath snake, 14 parts of Sophora alopecuroide, 6 parts of saline cistanche, 6 parts of barrenwort.
The preparation method for repairing neurovascular pharmaceutical composition, comprises the following steps：
1) glutinous rehmannia, pine bark, wide muscle rattan, Sagina subulata, arisaema cum bile, arisaema cum bile, saline cistanche and barrenwort are weighed by formula, washed
Only mechanical crushing is used after drying, is placed in marmite, the distilled water of 10-15 times of weight of solid content is added, intense fire is fried open, turns text
Fire decocts 30-50min, filters to obtain primary filtrate, and filter residue adds the distilled water of 10 times of amounts again, and slow fire is simmered 60-100min, filtered
Secondary filtrate, filtrate mixing twice, separation supernatant is standby；
2) ophidia of formula ratio is cleaned, 60-80 mesh is crushed to after slow fire frying 5-10min, and to obtain ophidia powder standby；
3) grape pip of formula ratio, Sophora alopecuroide are pulverized and sieved, obtains 60-80 mesh mixed powders standby；
4) by step 2) in prepare ophidia powder and step 3) in prepare mixed powder insert in extractor, add quality
Fraction is 95% ethanol solution, and stirring extraction obtains just extracted extract；
5) by step 4) in first extracted extract with 3 times amount purified water ultrasonic dissolutions, add sodium hydroxide solution regulation pH
To 1-3.5, add and stir extraction with the isometric chloroform of purified water, a layer chloroform extract is removed after layering, concentrate drying is obtained
Chloroform extract medicinal extract, chloroform is reclaimed；
6) by the Canola Oil of formula ratio and step 1) prepare supernatant, step 5) in prepare chloroform extract leaching
Cream is mixed, and in cooling down condensing removing moisture under vacuum condition, obtains thick paste；
7) by step 6) in prepare thick paste 2-3d is refrigerated in 0-4 DEG C of freezer, obtain pharmaceutical composition.
Embodiment 4
One kind repairs neurovascular pharmaceutical composition, is made up of the raw material below according to mass parts：28 parts of glutinous rehmannia, pine tree
12 parts of skin, 8 parts of grape pip, 3 parts of Canola Oil, 22 parts of wide muscle rattan, 19 parts of Sagina subulata, 13 parts of arisaema cum bile, 8 parts of lepidium seed,
4 parts of ophidia, 16 parts of Sophora alopecuroide, 8 parts of saline cistanche, 8 parts of barrenwort.
The preparation method for repairing neurovascular pharmaceutical composition, comprises the following steps：
1) glutinous rehmannia, pine bark, wide muscle rattan, Sagina subulata, arisaema cum bile, arisaema cum bile, saline cistanche and barrenwort are weighed by formula, washed
Only mechanical crushing is used after drying, is placed in marmite, the distilled water of 10-15 times of weight of solid content is added, intense fire is fried open, turns text
Fire decocts 30-50min, filters to obtain primary filtrate, and filter residue adds the distilled water of 10 times of amounts again, and slow fire is simmered 60-100min, filtered
Secondary filtrate, filtrate mixing twice, separation supernatant is standby；
2) ophidia of formula ratio is cleaned, 60-80 mesh is crushed to after slow fire frying 5-10min, and to obtain ophidia powder standby；
3) grape pip of formula ratio, Sophora alopecuroide are pulverized and sieved, obtains 60-80 mesh mixed powders standby；
4) by step 2) in prepare ophidia powder and step 3) in prepare mixed powder insert in extractor, add quality
Fraction is 95% ethanol solution, and stirring extraction obtains just extracted extract；
5) by step 4) in first extracted extract with 3 times amount purified water ultrasonic dissolutions, add sodium hydroxide solution regulation pH
To 1-3.5, add and stir extraction with the isometric chloroform of purified water, a layer chloroform extract is removed after layering, concentrate drying is obtained
Chloroform extract medicinal extract, chloroform is reclaimed；
6) by the Canola Oil of formula ratio and step 1) prepare supernatant, step 5) in prepare chloroform extract leaching
Cream is mixed, and in cooling down condensing removing moisture under vacuum condition, obtains thick paste；
7) by step 6) in prepare thick paste 2-3d is refrigerated in 0-4 DEG C of freezer, obtain pharmaceutical composition.
Embodiment 5
One kind repairs neurovascular pharmaceutical composition, is made up of the raw material below according to mass parts：25 parts of glutinous rehmannia, pine tree
10 parts of skin, 6 parts of grape pip, 2 parts of Canola Oil, 20 parts of wide muscle rattan, 18 parts of Sagina subulata, 12 parts of arisaema cum bile, 7 parts of lepidium seed,
3 parts of ophidia, 15 parts of Sophora alopecuroide, 7 parts of saline cistanche, 7 parts of barrenwort.
The preparation method for repairing neurovascular pharmaceutical composition, comprises the following steps：
1) glutinous rehmannia, pine bark, wide muscle rattan, Sagina subulata, arisaema cum bile, arisaema cum bile, saline cistanche and barrenwort are weighed by formula, washed
Only mechanical crushing is used after drying, is placed in marmite, the distilled water of 10-15 times of weight of solid content is added, intense fire is fried open, turns text
Fire decocts 30-50min, filters to obtain primary filtrate, and filter residue adds the distilled water of 10 times of amounts again, and slow fire is simmered 60-100min, filtered
Secondary filtrate, filtrate mixing twice, separation supernatant is standby；
2) ophidia of formula ratio is cleaned, 60-80 mesh is crushed to after slow fire frying 5-10min, and to obtain ophidia powder standby；
3) grape pip of formula ratio, Sophora alopecuroide are pulverized and sieved, obtains 60-80 mesh mixed powders standby；
4) by step 2) in prepare ophidia powder and step 3) in prepare mixed powder insert in extractor, add quality
Fraction is 95% ethanol solution, and stirring extraction obtains just extracted extract；
5) by step 4) in first extracted extract with 3 times amount purified water ultrasonic dissolutions, add sodium hydroxide solution regulation pH
To 1-3.5, add and stir extraction with the isometric chloroform of purified water, a layer chloroform extract is removed after layering, concentrate drying is obtained
Chloroform extract medicinal extract, chloroform is reclaimed；
6) by the Canola Oil of formula ratio and step 1) prepare supernatant, step 5) in prepare chloroform extract leaching
Cream is mixed, and in cooling down condensing removing moisture under vacuum condition, obtains thick paste；
7) by step 6) in prepare thick paste 2-3d is refrigerated in 0-4 DEG C of freezer, obtain pharmaceutical composition.
Embodiment 1-5 prepare the frequent regulation prescription method of the neurovascular pharmaceutical composition of reparation be prepared into for treat and
Repair neurovascular pulvis, granule, pill, capsule, tablet.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Using specification as an entirety, the technical solutions in the various embodiments may also be suitably combined, forms those skilled in the art
It may be appreciated other embodiment.
Claims (5)
1. one kind repairs neurovascular pharmaceutical composition, it is characterised in that be made up of the raw material below according to mass parts：Glutinous rehmannia
20-30 parts, 5-15 parts of pine bark, 2-10 parts of grape pip, 1-3 parts of Canola Oil, wide 16-24 parts of muscle rattan, Sagina subulata 16-20
Part, 10-14 parts of arisaema cum bile, 4-10 parts of lepidium seed, 1-5 parts of ophidia, 10-20 parts of Sophora alopecuroide, 4-10 parts of saline cistanche, barrenwort 4-
10 parts.
2. according to claim 1 repair neurovascular pharmaceutical composition, it is characterised in that by below according to mass parts
Raw material be made：22-28 parts of glutinous rehmannia, 8-12 parts of pine bark, 4-8 parts of grape pip, 1-3 parts of Canola Oil, wide muscle rattan 18-22
Part, 17-19 parts of Sagina subulata, 11-13 parts of arisaema cum bile, 6-8 parts of lepidium seed, 2-4 parts of ophidia, 14-16 parts of Sophora alopecuroide, saline cistanche 6-
8 parts, 6-8 parts of barrenwort.
3. according to claim 1 repair neurovascular pharmaceutical composition, it is characterised in that by below according to mass parts
Raw material be made：25 parts of glutinous rehmannia, 10 parts of pine bark, 6 parts of grape pip, 2 parts of Canola Oil, 20 parts of wide muscle rattan, Sagina subulata 18
Part, 12 parts of arisaema cum bile, 7 parts of lepidium seed, 3 parts of ophidia, 15 parts of Sophora alopecuroide, 7 parts of saline cistanche, 7 parts of barrenwort.
4. a kind of preparation method of neurovascular pharmaceutical composition of reparation as described in claim 1-3 is any, its feature exists
In comprising the following steps：
1) glutinous rehmannia, pine bark, wide muscle rattan, Sagina subulata, arisaema cum bile, arisaema cum bile, saline cistanche and barrenwort are weighed by formula, cleans and dry in the air
Mechanical crushing is used after dry, is placed in marmite, the distilled water of 10-15 times of weight of solid content is added, intense fire is fried open, turns to be cooked by slow fire
30-50min is boiled, primary filtrate is filtered to obtain, filter residue adds the distilled water of 10 times of amounts again, and slow fire simmers 60-100min, filters secondary
Filtrate, filtrate mixing twice, separation supernatant is standby；
2) ophidia of formula ratio is cleaned, 60-80 mesh is crushed to after slow fire frying 5-10min, and to obtain ophidia powder standby；
3) grape pip and Sophora alopecuroide of formula ratio are pulverized and sieved, obtains 60-80 mesh mixed powders standby；
4) by step 2) in prepare ophidia powder and step 3) in prepare mixed powder insert in extractor, add mass fraction
For 95% ethanol solution, stirring extraction obtains just extracted extract；
5) by step 4) in first extracted extract with 3 times amount purified water ultrasonic dissolutions, add sodium hydroxide solution regulation pH to 1-
3.5, add and stir extraction with the isometric chloroform of purified water, a layer chloroform extract is removed after layering, concentrate drying obtains chloroform
Position medicinal extract, chloroform is reclaimed；
6) by the Canola Oil of formula ratio and step 1) prepare supernatant and step 5) in prepare chloroform extract leaching
Cream is mixed, and in cooling down condensing removing moisture under vacuum condition, obtains thick paste；
7) by step 6) in prepare thick paste 2-3d is refrigerated in 0-4 DEG C of freezer, obtain pharmaceutical composition.
5. any described frequent regulation prescription methods of the neurovascular pharmaceutical composition of reparation of claim 1-4 are prepared into for controlling
Treat and repair neurovascular pulvis, granule, pill, capsule, tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710039512.2A CN107184756A (en) | 2017-01-19 | 2017-01-19 | One kind repairs neurovascular pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710039512.2A CN107184756A (en) | 2017-01-19 | 2017-01-19 | One kind repairs neurovascular pharmaceutical composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107184756A true CN107184756A (en) | 2017-09-22 |
Family
ID=59871162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710039512.2A Pending CN107184756A (en) | 2017-01-19 | 2017-01-19 | One kind repairs neurovascular pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107184756A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357325A (en) * | 2000-12-08 | 2002-07-10 | 青岛大学 | Prepn of natural active body cell multiplication promoter |
| CN1927248A (en) * | 2005-09-06 | 2007-03-14 | 四川省中医药研究院 | Application of semen desc urainia oil in preparation of composition with cranial nerve regulation function |
| CN1943771A (en) * | 2005-10-08 | 2007-04-11 | 河北以岭医药研究院有限公司 | The pharmaceutical for treatment of vascular lesion through actions on the NEI network |
| CN1990022A (en) * | 2005-12-30 | 2007-07-04 | 辽宁新世纪制药有限公司 | Traditional Chinese medicine composition, its preparation and quality controlling means |
| CN106046001A (en) * | 2016-06-02 | 2016-10-26 | 尹小英 | Compound having neuron protection function as well as preparation method and application of compound |
-
2017
- 2017-01-19 CN CN201710039512.2A patent/CN107184756A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357325A (en) * | 2000-12-08 | 2002-07-10 | 青岛大学 | Prepn of natural active body cell multiplication promoter |
| CN1927248A (en) * | 2005-09-06 | 2007-03-14 | 四川省中医药研究院 | Application of semen desc urainia oil in preparation of composition with cranial nerve regulation function |
| CN1943771A (en) * | 2005-10-08 | 2007-04-11 | 河北以岭医药研究院有限公司 | The pharmaceutical for treatment of vascular lesion through actions on the NEI network |
| CN1990022A (en) * | 2005-12-30 | 2007-07-04 | 辽宁新世纪制药有限公司 | Traditional Chinese medicine composition, its preparation and quality controlling means |
| CN106046001A (en) * | 2016-06-02 | 2016-10-26 | 尹小英 | Compound having neuron protection function as well as preparation method and application of compound |
Non-Patent Citations (1)
| Title |
|---|
| 吴谋成: "《油菜籽加工与综合利用》", 30 June 2009, 中国轻工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101224196B1 (en) | Method for omega-3 of crude drug and containing extracts hippophae rhamnoides l. | |
| CN102343050B (en) | Eye ointment for treating eye diseases | |
| CN105233324A (en) | Anti-inflammatory antiphlogistic hemostatic sponge and preparing method of anti-inflammatory antiphlogistic hemostatic sponge | |
| CN106490604A (en) | A kind of anti-oxidant Green Tea Extract health care product and preparation method thereof | |
| CN103933405A (en) | Pharmaceutical composition for treating qi-blood deficiency burn, and preparation method thereof | |
| CN107184756A (en) | One kind repairs neurovascular pharmaceutical composition and preparation method thereof | |
| CN103385985A (en) | Chinese herbal medicine composition for quick connection of muscles and bones | |
| CN106474218A (en) | Fructus Chaenomelis ferment nutritional solution and preparation method thereof | |
| CN105012688A (en) | Traditional Chinese medicine ointment used for treating keratosis pilaris, and preparation method thereof | |
| CN105194443A (en) | Traditional Chinese medicine composition for treating infantile eczema and preparation method of composition | |
| CN104306817A (en) | Pharmaceutical composition for treating ephemeral fever of dairy cow and preparation method thereof | |
| CN106474439A (en) | A kind of have heat-clearing and toxic substances removing, the Chinese medicinal ointment of removing heat from blood and promoting blood circulation function and preparation method thereof | |
| CN102670699B (en) | Traditional Chinese medicine for curing internal hemorrhoid | |
| CN106620438A (en) | Pharmaceutical composition for treating infancy hemangioma | |
| CN101703657A (en) | External preparation for treating verruca vulgaris | |
| CN106110044A (en) | A kind of Chinese medicinal ointment treating eczema | |
| CN106668349A (en) | Traditional Chinese medicine composition used after hemobilia operation and preparation method thereof | |
| CN106266427A (en) | A kind of Traditional Chinese medicinal liquor treating nephropathy and preparation method thereof | |
| CN104436039A (en) | Antitumor preparation for treating gastric cancer and preparation method thereof | |
| CN104784666A (en) | Traditional Chinese medicine ointment for orthopedic nursing | |
| CN103861063A (en) | Traditional Chinese medicine composition for treating rheumatism and rheumatoid diseases and preparation method thereof | |
| CN111759948A (en) | Traditional Chinese medicine composition for repairing gastrointestinal mucosa and preparation method and application thereof | |
| CN104225343A (en) | Chinese herbal preparation for treating urinary tract infection and preparation method thereof | |
| CN113663015A (en) | A topical Chinese medicinal composition for treating vitiligo | |
| CN116747287A (en) | Plant formula for preventing and treating alcoholic liver and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170922 |
|
| RJ01 | Rejection of invention patent application after publication |